Shrinidhi Nathany

Dr. Shrinidhi Nathany


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2024 in The Lancet Regional Health - Southeast Asia
Verified
Journal Article
Open access
VNVanita Ann Noronha
Vanita Ann Noronha
ABAtul Budukh
Atul Budukh
PCPankaj Chaturvedi
Pankaj Chaturvedi
SASrikanth Anne
Srikanth Anne
APAnshu Punjabi
Anshu Punjabi
KPKumar Prabhash
Kumar Prabhash
Lung cancer varies between Caucasians and Asians. There have been differences recorded in the epidemiology, genomics, standard therapies and outcomes, with variations according to the geography and ethnicity which affect the decision for optimal treatment of the patients. To better understand the profile of lung cancer in Southeast Asia, with a focus on India, we have comprehensively reviewed the available data, and discuss the challenges and the way forward. A substantial proportion of patients with lung cancer in Southeast Asia are neversmokers, and adenocarcinoma is the common histopathologic subtype, found in approximately a third of the patients. EGFR mutations are noted in 23–30% of patients, and ALK rearrangements are noted in 5–7%. Therapies are similar to global standards, although access to newer modalities and molecules is a challenge. Collaborative research, political will with various policy changes and patient advocacy are urgently needed.

13 August 2021 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
PDF file
SNShrinidhi Nathany
Shrinidhi Nathany
GCGaurav Chatterjee
Gaurav Chatterjee
SGShruti Ghai
Shruti Ghai
NMNirmalya Roy Moulik
Nirmalya Roy Moulik
DSDhanalaxmi Shetty
Dhanalaxmi Shetty
NPNikhil Patkar
Nikhil Patkar

15 June 2022 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
PDF file
AMAnurag Mehta
Anurag Mehta
HDHimanshi Diwan
Himanshi Diwan
GGGarima Gupta
Garima Gupta
SNShrinidhi Nathany
Shrinidhi Nathany
SAShalini Agnihotri
Shalini Agnihotri
SDSurender Dhanda
Surender Dhanda
Background: Founder mutation is a heritable genetic alteration observed with high frequency in a geographically and culturally isolated population where one or more ancestors becomes the forebearer of the altered gene. The current study reports two founder mutations in the BRCA1 gene in the Nepalese people.Methods: Germline BRCA testing in all surface epithelial ovarian cancers and the selected case of breast, prostate, and pancreatic cancers has been the standard practice from 2016 to 2021. One thousand one hundred thirtythree probands were screened for germline BRCA variants by next generation sequencing. The variants were classified as per the American Society of Medical Genetics and Genomics recommendations. Pathogenic (class V) and likely pathogenic (class IV) were considered clinically relevant and utilized for cascade screening.Results: Nepalese population made up a subcohort of 5.12% (58/1,133) of probands tested for germline BRCA1/2 variants. Twenty-seven of these 58 tested harbored pathogenic genetic alterations in BRCA1/2 genes, with 23 being BRCA1 mutant. Sixteen of 23 BRCA1 mutant cases shared one common pathogenic mutation c.2214_2215insT (p.Lys739Ter) (NM_007294.4). Additionally, a second highly recurrent mutation in BRCA1 gene c.5068A>T (p.Lys1690Ter) (NM_007294.4) was noted in six patients from this population.Conclusions: The overwhelming abundance of the above two variants in a geographically confined population confers these two genetic alterations a status of founder mutations amongst the people of Nepal. A more extensive population-based study to reaffirm these findings will help establish a dual site-specific germline testing similar to the “Multisite-3-assay” in Ashkenazi Jews as the primary screening tool, especially in a resource-constrained environment.

1 June 2025 in Neuropathology
Verified
Journal Article
Closed access
SDSUMANTA DAS
SUMANTA DAS
BCBheru Dan Charan
Bheru Dan Charan
SNShrinidhi Nathany
Shrinidhi Nathany
RGRakesh Kumar Gupta
Rakesh Kumar Gupta
MSMehar Chand Sharma
Mehar Chand Sharma
SASunita Ahlawat
Sunita Ahlawat

27 October 2021 in Future Oncology
Verified
Journal Article
Closed access
UBUllas Batra
Ullas Batra
SNShrinidhi Nathany
Shrinidhi Nathany
MSMansi Sharma
Mansi Sharma
PJParveen Jain
Parveen Jain
SDSurender Dhanda
Surender Dhanda
AMAnurag Mehta
Anurag Mehta
Aims: With the International Association for the Study of Lung Cancer (IASLC) recommendations promoting liquid biopsy as a primary detection tool, a new era of research has begun. The authors aimed... Lay abstract Lung cancer is one of the most common malignancies and has been known to have a dismal outcome. However, owing to evolution in the knowledge of disease biology and processes, many mole...

15 September 2021 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
PDF file
AMAnurag Mehta
Anurag Mehta
SNShrinidhi Nathany
Shrinidhi Nathany
ACAanchal Chopra
Aanchal Chopra
SMSakshi Mattoo
Sakshi Mattoo
DKDushyant Kumar
Dushyant Kumar
MPManoj Kumar Panigrahi
Manoj Kumar Panigrahi
Background: A mutation/deletion involving donor or acceptor sites for exon 14 results in splicing out of exon 14 of the mesenchymal epithelial transition (MET) gene and is known as “MET exon 14 skipping” (ΔMET14). The two recent approvals with substantial objective responses and improved progression-free survival to MET inhibitors namely capmatinib and tepotinib necessitate the identification of this alteration upfront. We herein describe our experience of ΔMET14 detection by an mRNA-based assay using polymerase chain reaction followed by fragment sizing. Methods: This is a home brew assay which was developed with the concept that the transcripts from true ΔMET14 will be shorter by ~140 bases than their wild type counterparts. The cases which were called MET exon 14 skipping positive on next-generation sequencing (NGS) were subjected to this assay, along with 13 healthy controls in order to establish the validity for true negatives. Results: Thirteen cases of ΔMET14 mutation were detected on NGS using RNA-based sequencing. Considering NGS as a gold standard, the sizing assay using both gel and capillary electrophoresis that showed 100% specificity for both with concordance rates of 84.6% and 88.2% with NGS, respectively, were obtained. Conclusions: Owing to the cost-effective nature and easy to use procedures, this assay will prove beneficial for small- and medium-sized laboratories where skilled technical personnel and NGS platforms are unavailable.